Viewing Study NCT07213960

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:06 AM
Ignite Modification Date: 2026-05-21 @ 12:56 PM
Study NCT ID: NCT07213960
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-10-09
First Post: 2025-09-15
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
Sponsor: Apellis Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None FSGS View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Glomerulosclerosis View
None Focal Segmental View
None Child View
None Adult View
None Peptides View
None Cyclic View
None Complement Inactivator Proteins View